The landscape of dementia analysis has evolved radically with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-based tests that will detect Alzheimer's pathology several years in advance of symptoms emerge. While these technological developments symbolize impressive development in knowledge neurodegenerative